Patents Assigned to Arbutus Biopharma Corporation
-
Publication number: 20240148875Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.Type: ApplicationFiled: January 12, 2024Publication date: May 9, 2024Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
-
Publication number: 20240100166Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.Type: ApplicationFiled: September 5, 2023Publication date: March 28, 2024Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
-
Publication number: 20240066129Abstract: Disclosed herein are lipid compositions comprising a cationic lipid of formula (I), a neutral lipid, a sterol and a PEG or PEG-modified lipid, wherein formula (I) is (F). Also disclosed are methods of producing the cationic lipid of formula (I).Type: ApplicationFiled: February 16, 2023Publication date: February 29, 2024Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Michael E. Jung
-
Patent number: 11904052Abstract: Certain embodiments of the invention provide methods of ameliorating an infusion reaction in a mammal in need thereof.Type: GrantFiled: May 20, 2022Date of Patent: February 20, 2024Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Jeffrey P. Bechard, Wayne J. Wallis
-
Publication number: 20240050463Abstract: The invention provides therapeutic combinations and therapeutic methods that are useful for treating Hepatitis B.Type: ApplicationFiled: November 29, 2022Publication date: February 15, 2024Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Andrea CUCONATI, Amy C. H. LEE, Cornelis A. RIJNBRAND, Michael J. SOFIA
-
Publication number: 20240052349Abstract: The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, an siRNA, and optional linking groups. The conjugates are useful to target siRNA.Type: ApplicationFiled: November 5, 2021Publication date: February 15, 2024Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Owen M. DALY, Amy C. H. LEE, Michael J. SOFIA, Emily P. THI
-
Patent number: 11896672Abstract: The invention provides conjugates that comprise a targeting moiety, a nucleic acid, and optional linking groups as well as synthetic intermediates and synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic nucleic acids to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).Type: GrantFiled: April 11, 2017Date of Patent: February 13, 2024Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: James Heyes, Richard J. Holland, Alan D. Martin, Mark Wood
-
Publication number: 20240042039Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure wherein: R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ?-aminoalkyls, ?-(substituted)aminoalkyls, ?-phosphoalkyls, ?-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).Type: ApplicationFiled: March 31, 2023Publication date: February 8, 2024Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Muthiah Manoharan, Muthusamy Jayaraman, Kallanthottathil G. Rajeev, Laxman Eltepu, Steven Ansell, Jianxin Chen
-
Publication number: 20240035030Abstract: The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: June 7, 2023Publication date: February 1, 2024Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Ed Yaworski, Lloyd B. Jeffs, Lorne R. Palmer
-
Publication number: 20230381319Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.Type: ApplicationFiled: February 16, 2023Publication date: November 30, 2023Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Jayaprakash K. Nair, Martin Maier, Laxman Eltepu
-
Publication number: 20230372245Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: May 16, 2023Publication date: November 23, 2023Applicant: Arbutus Biopharma CorporationInventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan
-
Patent number: 11786598Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.Type: GrantFiled: July 25, 2022Date of Patent: October 17, 2023Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
-
Publication number: 20230248831Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.Type: ApplicationFiled: July 25, 2022Publication date: August 10, 2023Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
-
Patent number: 11718852Abstract: The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: GrantFiled: March 16, 2021Date of Patent: August 8, 2023Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Ed Yaworski, Lloyd B. Jeffs, Lorne R. Palmer
-
Patent number: 11712476Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention formula (I) provides lipids having the following structure XXXIII wherein: R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ?-aminoalkyls, ?-(substituted)aminoalkyls, ?-phosphoalkyls, ?-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).Type: GrantFiled: June 24, 2021Date of Patent: August 1, 2023Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Muthiah Mancharan, Muthusamy Jayaraman, Kallanthottathil G. Rajeev, Laxman Eltepu, Steven Ansell, Jianxin Chen
-
Patent number: 11702427Abstract: The present invention includes in one aspect substituted 2-oxo-1,2,5,6-tetrahydrobenzo[h]quinoline-3-carboxylic acids, analogues thereof, and compositions comprising the same, which can be used to treat and/or prevent hepatitis B virus (HBV) infection and/or hepatitis D virus (HDV) in a patient.Type: GrantFiled: March 11, 2019Date of Patent: July 18, 2023Assignee: Arbutus Biopharma CorporationInventors: Shuai Chen, Bruce D. Dorsey, Yi Fan, Dimitar B. Gotchev, Jorge Quintero
-
Publication number: 20230212578Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as siRNA that target ApoC3 and ANGPTL3 expression, lipid particles comprising one or more (e.g., a combination) of the therapeutic nucleic acids, and methods of delivering and/or administering the lipid particles (e.g., for treating hypertriglyceridemia in humans).Type: ApplicationFiled: November 30, 2022Publication date: July 6, 2023Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Ting CHIU, Narayanan HARIHARAN, Amy C. H. LEE, Christopher Justin PASETKA, Janet Ruth PHELPS, Nicholas Michael SNEAD, Andrew Anthony WIECZOREK
-
Publication number: 20230174459Abstract: Compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described.Type: ApplicationFiled: July 13, 2022Publication date: June 8, 2023Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Akin Akinc, Jayaprakash K. Nair, Muthusamy Jayaraman, Martin Maier
-
Publication number: 20230165973Abstract: The present invention provides compositions comprising mRNA molecules encapsulated within lipid particles. The lipid particles comprise a cationic lipid, a non-cationic lipid, and an mRNA molecule that is encapsulated within the lipid particle. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease. The invention also provides cationic lipids that are useful for preparing the compositions of the invention.Type: ApplicationFiled: August 31, 2022Publication date: June 1, 2023Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: James HEYES, Lorne R. PALMER, Stephen P. REID, Edward D. YAWORSKI, Ian MACLACHLAN, Mark WOOD, Alan D. MARTIN
-
Publication number: 20230113948Abstract: The invention provides synthetic processes and synthetic intermediate compounds that can be used to prepare therapeutic conjugates. The invention also provides methods for treating HBV and/or HDV infection in a human by administering a therapeutic conjugate prepared by the synthetic methods of the invention.Type: ApplicationFiled: December 17, 2020Publication date: April 13, 2023Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Mahesh PALLERLA, Ganapati Reddy PAMULAPATI, Jan SPINK